Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Elekta to launch MOSAIQ oncology information system throughout McLaren's cancer network

The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care to launch MOSAIQ oncology information system throughout McLaren's cancer network.

From Elekta 18 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Takeda expands commercial platform in Israel

Takeda Pharmaceuticals International GmbH today announced further expansion of its commercial platform with the establishment of its wholly-owned subsidiary in Israel. Together with Algeria, Ecuador, Peru, Singapore and Vietnam, Israel is the sixth sales entity Takeda has opened this year to reinforce its platform in growth markets.

18 Dec 2013

Elekta and McLaren Health Care to launch MOSAIQ oncology information system

The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care to launch MOSAIQ® oncology information system throughout McLaren's cancer network.

From Elekta 18 Dec 2013

UCLA scientists receive $21M grant to conduct groundbreaking clinical trials on stem cell science

Scientists from UCLA are now bringing their groundbreaking stem cell science directly to patients in two exciting new clinical trials scheduled to begin in early 2014, thanks to funding from California's stem cell agency.

17 Dec 2013

Selenium fails to protect NSCLC patients against second primary tumors

Selenium supplementation does not reduce the risk for second primary tumors in patients with resected non–small-cell lung cancer, researchers say.

17 Dec 2013

Unexpected toxicity of pazopanib/pemetrexed in NSCLC halts study

A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm.

17 Dec 2013

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

BerGenBio AS, an oncology biopharmaceutical company, announces that preclinical data demonstrating that BGB324 has potential application as a novel treatment for Chronic Myeloid Leukemia, was presented in a poster at the Annual Meeting of the American Society of Hematology, which took place on December 7-10, 2013.

17 Dec 2013

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.

17 Dec 2013

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Ipsen today announced positive initial results from the double-blind phase III study of Dysport (abobotulinumtoxinA) in Adult Upper Limb spasticity. Regarding the primary endpoints, treatment with Dysport showed statistically significant response versus placebo in the improvement of muscle tone, as measured by the Modified Ashworth Scale.

17 Dec 2013

Mirimus develops enhanced tools for reversible gene suppression

Over the last decades, RNA interference (RNAi) has become an indispensable tool for functional genetic studies by harnessing the power of a cell intrinsic mechanism enabling reversible gene silencing.

17 Dec 2013

Two existing drugs show promise as potential treatments for cervical cancer

Two existing drugs - one the active ingredient in an anti-fungal medication and the other now used to control iron levels in the blood - both show promise as potential treatments for cervical cancer, according to newly published research by scientists at Rutgers New Jersey Medical School.

17 Dec 2013

New regulation for cancer-causing protein may help develop targeted therapies

Researchers with the Cincinnati Cancer Center (CCC) and the University of Cincinnati (UC) Cancer Institute have discovered a new regulation for the cancer-causing protein KRas which may help with the development of targeted therapies for patients with a KRas mutation.

17 Dec 2013

Scientists continue work to end chemotherapy pain

With this year's $600,000 grant from the Leukemia & Lymphoma Society and $1.5 million grant from the NIH, a Saint Louis University investigator is continuing her work to end chemotherapy pain. Noted pain researcher Daniela Salvemini, Ph.D., is using the funding to capitalize on her recent finding published in Pain, a breakthrough that helps scientists understand a molecular pathway by which pain occurs with certain anti-cancer drugs.

17 Dec 2013

PAM50 FDA-cleared breast cancer test to be launched at ARUP Laboratories

The PAM50 breast cancer signature developed at the University of Utah and Huntsman Cancer Institute received FDA approval and will launch at ARUP Laboratories in Salt Lake City. The test utilizes gene expression data from 50 genes weighted together with clinical variables to generate a risk category and numerical score to assess a patient's risk of distant recurrence at ten years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), Hormone Receptor-Positive (HR+) breast cancer.

16 Dec 2013

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC

Erlotinib as first-line therapy in patients with advanced non-small-cell lung cancer is equivalent to chemotherapy with regard to overall survival, an “all-comers” phase II trial has shown.

16 Dec 2013

Glioblastoma multiforme patients treated with experimental vaccine show improved survival

Patients with recurrent glioblastoma multiforme treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro-Oncology and accompanied by an editorial highlighting the importance of the trial.

16 Dec 2013

OncoSec Medical reports positive interim data from OMS-I100 Phase 2 trial for metastatic melanoma

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced positive interim data from its ongoing Phase 2 trial of OMS-I100 in the treatment of metastatic melanoma. The results were presented by principal investigator Adil Daud, MD, at the Advances in Cancer Immunotherapy meeting at the University of California San Francisco.

16 Dec 2013

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Cellular Biomedicine Group, Inc., a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma, the most common type of liver cancer.

16 Dec 2013

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes.

16 Dec 2013

Oncology News and Research

Further Reading

Elekta to launch MOSAIQ oncology information system throughout McLaren's cancer network

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Takeda expands commercial platform in Israel

Elekta and McLaren Health Care to launch MOSAIQ oncology information system

UCLA scientists receive $21M grant to conduct groundbreaking clinical trials on stem cell science

Selenium fails to protect NSCLC patients against second primary tumors

Unexpected toxicity of pazopanib/pemetrexed in NSCLC halts study

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Mirimus develops enhanced tools for reversible gene suppression

Two existing drugs show promise as potential treatments for cervical cancer

New regulation for cancer-causing protein may help develop targeted therapies

Scientists continue work to end chemotherapy pain

PAM50 FDA-cleared breast cancer test to be launched at ARUP Laboratories

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC

Glioblastoma multiforme patients treated with experimental vaccine show improved survival

OncoSec Medical reports positive interim data from OMS-I100 Phase 2 trial for metastatic melanoma

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Cancer Research - Second Edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News